Bright Minds Biosciences Inc Ordinary Shares DRUG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
DRUG SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Bright Minds Biosciences
Bright Minds Biosciences Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Bright Minds Biosciences (DRUG)
Bright Minds Biosciences Provides Update About Planned Study with BMB-101 in Developmental and Epileptic Encephalopathies
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
Bright Minds Biosciences to Present at Upcoming Conferences
Trading Information
- Previous Close Price
- $20.70
- Day Range
- $20.93–20.99
- 52-Week Range
- $17.53–124.24
- Bid/Ask
- $20.98 / $21.72
- Shares Outstanding
- 9.86M
- Market Cap
- $204.19M
- Volume/Avg
- 4,666 / 175,182
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 25
Valuation
Metric | DRUG |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.94 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | DRUG |
|---|---|
Quick Ratio | 121.44 |
Current Ratio | 121.97 |
Interest Coverage | — |
Quick Ratio
DRUG
Profitability
Metric | DRUG |
|---|---|
Return on Assets (Normalized) | −14.84% |
Return on Equity (Normalized) | −15.04% |
Return on Invested Capital (Normalized) | −19.09% |
Return on Assets
DRUG
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|@Pkrbbh | LOCK|^?NX | $138B | |||
| Moderna Inc MRNA | LOCK|!D<@$! | LOCK|x^ | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|%^cVP<P | LOCK|%Q<f | $93B | |||
| argenx SE ADR ARGX | LOCK|Mwqz<@ | LOCK|Hq | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|!RpnxKX | LOCK|&^D | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|&BdkH@Sd | LOCK|%sfF | $30B | |||
| Incyte Corp INCY | LOCK|dZNNlV | LOCK|bCK | $24B | |||
| BioNTech SE ADR BNTX | LOCK|^?<yFB | LOCK|wcp | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|Q?XW!>M | LOCK|SLY$& | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|&!sS!? | LOCK|@% | $15B |
United States